Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II Study of gemcitabine and capecitabine in chemotherapy-refractory metastatic colorectal cancer
2011-004182-33Phase 2Completed
- Sponsor
- Vejle Hospital
- Start
- Sep 2011
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of gemcitabine and capecitabine in metastatic colorectal adenocarcinoma (mCRC) and colorectal cancer (CRC), sponsored by Vejle Hospital. Primary endpoint: Disease control rate at 3 months. Started Sep 2011; status: completed.
02
Drugs
gemcitabinecapecitabine
03
Conditions
metastatic colorectal adenocarcinoma (mCRC)colorectal cancer (CRC)
Beyond the preview
Go deeper on 2011-004182-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2011-004182-33.